This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Madrigal Pharmaceuticals’s 8K filing here.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Recommended Stories
- Five stocks we like better than Madrigal Pharmaceuticals
- Election Stocks: How Elections Affect the Stock Market
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Top Biotech Stocks: Exploring Innovation Opportunities
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- MarketBeat Week in Review – 01/13 – 01/17
